ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

US Judge Upholds Validity Of Merck's Vytorin Patent

By Peter Loftus Of DOW JONES NEWSWIRES A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (MRK) Vytorin cholesterol-lowering drug, which could stave off competing generic copies for several years. In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said a patent for Vytorin was valid and enforceable. Merck, based in Whitehouse Station, N.J., said in a recent regulatory filing it expects its U.S. exclusivity for Vytorin and a related drug, Zetia, to expire in April 2017. Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell a generic version of Vytorin before its patent protection expired, arguing that the patent was invalid and unenforceable. Schering-Plough, which was acquired by Merck in 2009, filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's product. A trial was held in December 2011, leading to Judge Linares's opinion Friday. On a conference call with analysts Friday morning, Merck Chief Executive Kenneth Frazier said he was anticipating a favorable decision. "We believe this is a patent that is valid and enforceable," he said. A Mylan spokeswoman couldn't immediately be reached. Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million. Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval. -By Peter Loftus, Dow Jones Newswires; +1-215-982-5581;

Stock News for Merck (MRK)
11/25/201508:00:07How Big Could This Drug Be for Opko Health?
11/24/201512:35:00Merck Announces Increased Quarterly Dividend
11/24/201507:41:03This Metric Implies That It Might Be Time to Buy Big Pharma Stocks
11/23/201510:01:03Can Merck & Co. Take Down Gilead Sciences?
11/22/201509:12:02Beyond Chemotherapy: 4 Unique Ways Drug Developers Are Fighting...
11/21/201516:30:00Merck Announces Initial Results for KEYTRUDA® (pembrolizumab...
11/21/201509:04:08Gilead Sciences Inc. Has Plenty of Room to Run in Hepatitis C
11/20/201517:55:00Celldex Vaccine Rindopepimut Cuts Death Risk From Brain Cancer...
11/20/201507:40:02Merck & Co.'s Cholesterol-Buster Program Isn't (Yet) an Exercise...
11/19/201506:30:00Lilly and Merck Expand Immuno-oncology Collaboration with Phase...
11/18/201510:18:035 Things Merck & Co., Inc. Wants You to Know
11/17/201515:52:03Why Novavax Inc Is Moving Higher Today
11/17/201510:59:02Here's Why Advaxis' Stock Gained 11% in October
11/17/201508:00:00New Studies Investigating the Use of KEYTRUDA® (pembrolizumab...
11/16/201509:19:033 High-Yield Dividend Stocks You Don't Have to Babysit
11/16/201508:30:00Merck Announces Presentation of Results from Two Phase 2 Studies...
11/15/201518:00:03Exelixis, Inc. Earnings: Riding the Meteor
11/14/201519:00:00Merck Announces Presentation of Phase 3 Results of Investigational...
11/14/201519:00:00Merck to Release Findings from Integrated Analysis of Six Phase...
11/13/201508:41:03Hepatitis C Treatment in 2016: Will Gilead Sciences or AbbVie...

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations